Efficacy and safety analysis of PD-1 monoclonal antibody combined with chemotherapy in the treatment of esophageal cancer
Objective To explore the efficacy and safety of programmed death receptor 1 (PD-1) monoclonal antibody combined with chemotherapy in the treatment of esophageal cancer. Methods A total of 80 esophageal cancer patients from the Taizhou Second People's Hospital from January 2022 to December 2023 were selected as the subjects of this study. They were divided into a study group and a control group according to random number table method,with 40 cases in each group. The esophageal cancer patients in the control group were treated with paclitaxel (albumin binding)+cisplatin,while the esophageal cancer patients in the study group were treated with PD-1 monoclonal antibody combined with paclitaxel (albumin binding)+cisplatin. The levels of PD-1,programmed death-ligand-1(PD-L1),immune function (CD3+,CD4+and CD4+/CD8+),therapeutic efficacy and the total incidence rate of adverse reactions were compared between the two groups. Results The levels of PD-1 and PD-L1 of the patients in the study group were significantly lower than those of the control group,and the difference was statistically significant (P<0.05). The immune function indexes of the patients in the study group were significantly higher than those of the control group,and the difference was statistically significant (P<0.05). The total effective rate of treatment of the patients in the study group was significantly higher than that of the control group,and the difference was statistically significant (P<0.05). The total incidence rate of adverse reactions of the patients in the study group was significantly lower than that of the control group,and the difference was statistically significant (P<0.05). Conclusion The use of PD-1 monoclonal antibody combined with paclitaxel+cisplatin chemotherapy can effectively improve the clinical efficacy and immune function of esophageal cancer patients,and reduce the levels of PD-1,PD-L1 and the incidence of adverse reactions in patients,which is worthy of popularization and application.
万方数据
维普
